Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLANG versus FLANG plus cyclosporine for relapsed or refractory acute myeloid leukemia
IRCT20250605066068N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jun 2025
- Modality
- Small Molecules, Peptides, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cyclosporine, fludarabine, cytarabine, mitoxantrone and granulocyte colony-stimulating factor in acute myeloid leukemia (AML) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Bone marrow remission rate, Drug toxicity and 1 more. Started Jun 2025; status: completed.
02
Drugs
cyclosporinefludarabinecytarabinemitoxantronegranulocyte colony-stimulating factor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on IRCT20250605066068N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250605066068N1.